The initial participant in the U.S. joins the phase III global multi-center clinical trial for telitacicept targeting myasthenia gravis, marking a significant milestone.

Elevation Oncology Releases Encouraging Early Results from Phase 1 Trial of EO-3021 in Patients with Advanced Non-Resectable or Metastatic Solid Tumors.

This expansion now encompasses Merck’s investigational product MK-6070, a T-cell engager targeting delta-like ligand 3 (DLL3).

Equillium Reports Favorable Interim Results from Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease.

Global pharma major Lupin Limited, revealed the introduction of its first biosimilar in Canada, Rymti®, via its collaborator, Sandoz Canada.

Global Pharma major Lupin Limited revealed the completion of an international Phase 3 clinical trial for its biosimilar LUBT010.

Levicept Reveals Successful Phase II Trial Results for LEVI-04, a Novel Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis.

First Patient Enrolled in US Phase 2 Trial of Akeso’s Ligufalimab and Azacitidine Combo for Myelodysplastic Syndrome.

Genmab A/S revealed that it will take over full responsibilities for both the ongoing development and possible commercialization of acasunlimab.

Rezolute Receives FDA Approval for Phase 3 IND Study of RZ358 for Hypoglycemia Caused by Tumor-Induced Hyperinsulinism.

Imbrium Therapeutics L.P., has filed an Investigational New Drug Application with the U.S. Food and Drug Administration to assess the use of sunobinop for potentially treating moderate to severe alcohol use disorder.

Bayer Reveals Phase III Study Results: FINEARTS-HF Achieves Key Goal for KERENDIA® (finerenone) in Heart Failure Patients with Mildly Reduced or Normal Ejection Fraction.